AMGN

#80
Amgen Inc. - Common Stock
336.7 0 USD
+0.07%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
335.47
337.47
Faixa anual
267.83
391.29
Mudança diária
+0.07%
Mudança mensal
-1.19%
Mudança em 6 meses
-1.90%
Mudança anual
+18.83%
Fechamento anterior
336.4 8
Open
335.4 7
Mínimo
335.4 7
High
337.4 7
Volume
3 578
Abrir gráfico completo Full chart

Financials

Visão geral Relatórios Estatísticas Dividendos
Trimestral Ano
  • Market Capitalization 181.72 B
  • Employee 32 K
  • Founded 1980
  • CEO Robert A. Bradway
  • Website www.amgen.com
  • Headquarter Delaware, United States
  • FIGI BBG000BBS2Y0
  • Industry Fabricantes de medicamentos - gerais
Receita total
Lucro líquido
Lucro básico por ação
Dívida total
Fluxo de caixa livre
Caixa e equivalentes de caixa
Índice preço/lucro
23
Índice preço/fluxo de caixa
4.83
Dividendos por ação
9.66
Rendimento de dividendos, %
2.95

Amgen Inc. - Common Stock

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp to stimulate erythropoiesis. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000.

Notícias